Shirley Ying

Shirley Ying is an accomplished executive in the pharmaceutical industry, currently serving as the Executive Director of US Hematology, Enterprise Strategy and Performance at Bristol Myers Squibb (BMS). In this role, she is responsible for leading strategic initiatives and performance analytics for BMS's hematology and cell therapy franchises, which generate over $12 billion in annual revenue. Her work involves synthesizing market research and data analytics to provide actionable insights that drive product growth and commercial success.1

Professional Background

• Bristol Myers Squibb (2018 - Present): Prior to her current role, Ying served as the Executive Director of Business Insights and Analytics at Celgene, which was integrated into BMS. Here, she led strategic forecasting and analytics for the US Hematology & Cell Therapy Franchise.1

• Komodo Health (2017 - 2018): She held the position of VP, Head of Enterprise Data Strategy and Commercial Analytics, where she developed enterprise data strategies for the life sciences sector.1

• Novartis Pharmaceuticals (2007 - 2017): Ying was the Director of Business Insights Lead for Oncology, focusing on business planning and forecasting processes across various oncology franchises.1

• American Express (2006 - 2007) and General Motors (2000 - 2006): She began her career in finance and analytics, contributing to significant projects in both organizations.1

Education and Skills

Shirley Ying holds a degree from The Ohio State University. She is recognized for her strategic thinking and expertise in commercial performance measurement, data analytics, and market research within the pharmaceutical industry. Additionally, she is bilingual in English and Chinese, enhancing her ability to operate in diverse environments.1

Overall, Shirley Ying's extensive experience in pharmaceutical strategy and analytics positions her as a key leader at Bristol Myers Squibb, particularly in addressing the challenges and opportunities within the hematology sector.